Deep transfer learning of cancer drug responses by integrating bulk and single-cell RNA-seq data

a. What is the problem the article's trying to address?

Current drug response prediction methods are designed for bulk RNA-seq data and cannot cope with the heterogeneity present in single-cell RNA-seq (scRNA-seq) data. There is a need for computational methods to predict drug response at the single-cell level to better understand and predict how individual cancer cells respond to treatment, given the diversity in cancer cell populations. Thus, this work presents a new tool based on a domain-adaptive neural network algorithm to solve a pressing problem in drug biology.



b. What are the related works in the field and why there is still a need to propose new solutions?

Related works include deep learning methods applied to scRNA-seq data and existing drug-response prediction models based on bulk RNA-seq data. Despite advancements, current methods are insufficient due to limited training data at the single-cell level and the complexity of single-cell data compared to bulk data. Deep transfer learning (DTL) models have been used to leverage bulk data for cancer drug response predictions, but their application to single-cell data remains underexplored. Hence, new solutions are needed to bridge this gap and accurately predict drug responses at the single-cell level .

c. What do the authors propose? Describe their solution, input data, processing, metrics, etc.

The authors propose scDEAL (single-cell Drug rEsponse Analysis), a deep transfer learning framework designed to predict cancer drug responses by integrating bulk RNA-seq data with scRNA-seq data.

Bulk RNA-seq data from the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE), and scRNA-seq data from various studies. Combining bulk data from GDSC and CCLE databases enhanced prediction power, increasing F1-scores by 130% and 69% compared to using only GDSC or CCLE data, respectively.

Processing via extracting gene features from both bulk and single-cell data using denoising autoencoders (DAEs). Using DAE with cell-type regularization improved performance, showing a 36% and 9% increase in F1-scores compared to using common autoencoders or DAE alone. UMAP results confirmed that cell-type regularization better preserved the heterogeneity of scRNA-seq data.

Training a deep transfer learning model to harmonize and transfer knowledge from bulk to single-cell data. Using integrated gradient interpretation to identify signature genes associated with drug response.

The performance of scDEAL is evaluated using metrics such as F1-score, area under the receiver operating characteristic (AUROC), average precision (AP) score, precision, recall, Adjusted Mutual Information (AMI), and Adjusted Rand Index (ARI).



d. What are the major results and achievements of the proposed solution? How do they relate to the existing methods and what are the limitations?

High accuracy in cell drug response prediction demonstrated by an average F1-score of 0.892, AUROC of 0.898, and AP score of 0.944 on six scRNA-seq benchmark datasets. Identify gene signatures that contribute to drug sensitivity or resistance, improving model interpretability. Reliable predictions even when reassembling data sets, demonstrating the robustness of the method.

Compared with existing methods, scDEAL effectively transfers knowledge from bulk data to single-cell data, addressing the problem of drug response heterogeneity in single-cell systems. However, limitations include challenges in predicting drug response across species due to genetic variations and limited reference data for drug-treated mouse scRNA-seq data.



e. What are the conclusions?

The scDEAL system effectively improves drug response prediction at the single-cell level by leveraging bulk RNA-seq data using transfer learning. This approach accounts for the heterogeneity inherent in cancer cell populations, providing more accurate predictions of drug efficacy at the single-cell level. By integrating data from the GDSC and CCLE databases and using autoencoders with denoise and cell type regularization, scDEAL improves the identification of gene signatures associated with drug sensitivity and resistance. This system has significant implications for personalized medicine as it can better predict individual cellular response to treatment, thereby helping to develop more targeted and effective cancer treatments. The comprehensive validation of scDEAL highlights its potential to bridge the gap between bulk and single-cell analyses, offering a robust tool to advance our understanding of cancer biology and therapeutic responses.